Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

CME Outfitters

A Deeper Dive into NASH Diagnosis and Treatment: An Augmented Reality Experience

Access Activity

Overview / Abstract:

Statement of Need

Obesity and diabetes are on the rise, leading to an increased prevalence of non-alcoholic fatty liver disease (NAFLD), which in some cases may progress to non-alcoholic steatohepatitis (NASH). NAFLD effects approximately 30% of the U.S. population, with NASH effecting about 5%. NASH comes with a significant risk of progression to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Disease models project that the number of individuals with end-stage liver disease will double - or possibly triple - by 2030.

With the majority of high-risk patients first seen in the primary care setting, it is imperative that internists and primary care physicians identify patients at risk for NASH. Although liver biopsy was previously the best test for identifying the critical endpoints of NASH, several noninvasive, yet effective, tests have been developed recently that have the potential to be implemented in primary care settings. While currently there are no approved treatments for NASH, novel targeted therapies are being studied in phase III clinical trials, some of which have shown promising results.

In this CME Outfitters virtual symposium, expert faculty utilize Augmented Reality (AR) to visually dive into NASH, with particular focus on risk stratification, diagnosis, and emerging targeted therapies.

Learning Objectives

At the end of this CE activity, participants should be able to:
- Identify risk factors associated with NAFLD and NASH.
- Utilize appropriate noninvasive tests for the identification of NASH in patients with NAFLD.
- Evaluate novel therapeutic targets and clinical evidence on emerging therapies for NASH.

The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify risk factors associated with NAFLD and NASH.
- Describe appropriate noninvasive tests for the identification of NASH in patients with NAFLD.
- Evaluate novel therapeutic targets and clinical evidence on emerging therapies for NASH.

Expiration

Apr 22, 2021

Discipline(s)

Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME

Format

Live / Seminar, Online, Webinar / Webcast / Video

Credits / Hours

1.5 AMA PRA Category 1 Credit

Accreditation

ACCME, ACPE, ABIM MOC, CBRN

Is This Activity Certified for "Live" Credit?

YES

Presenters / Authors / Faculty

Mazen Noureddin, MD, MHSc
Director, Fatty Liver Program
Division of Digestive & Liver Diseases
Comprehensive Transplant Center
Cedars Sinai Medical Center
Los Angeles, CA

Scott C. Howell, DO
AIDS Healthcare Foundation
Los Angeles, CA

Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
Chairman, Department of Medicine
Professor Medicine
Inova Fairfax Hospital
Fairfax, VA

Sponsors / Supporters / Grant Providers

Supported by an educational grant from Intercept Pharmaceuticals, Inc.

Keywords / Search Terms

CME Outfitters fatty liver disease, liver disease, internal medicine, ACP, ABIM, MOC, NASH, NAFLD, non-alcoholic steatohepatitis, fatty liver, gastroenterology, hepatology Free CE CME Live CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.